The American Society of Clinical Oncology (the Society) is governed by a volunteer Board of Directors (including five Board officers) elected by ASCO’s member oncologists. The ASCO Chief Executive Officer serves on the Board as well. Elected Board members are cancer physicians and clinical researchers who volunteer their time to ASCO. Board members are not paid for their service, although their institutions receive stipends to partially cover the time and administrative resources dedicated to ASCO.

View the Disclosures for the Society Board of Directors at the bottom of each individual’s bio. Please direct any questions related to Board members' disclosures to COI@asco.org.

Clifford A. Hudis, FACP, FASCO, MD
Chief Executive Officer, ASCO; Executive Vice Chair, Conquer Cancer, the ASCO Foundation; and Chair, CancerLinQ
x

Dr. Hudis is the Chief Executive Officer of the American Society of Clinical Oncology (ASCO). He also serves as the Executive Vice Chair of its Conquer Cancer Foundation and Chair of ASCO’s CancerLinQ. Dr. Hudis previously served in a variety of volunteer and leadership roles at ASCO, including as its President during the Society’s 50th anniversary year (2013-14). Before coming to ASCO full-time, he was the Chief of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City and Professor of Medicine at the Weill Medical College of Cornell University. As CEO of ASCO, Dr. Hudis is responsible for delivering on the board’s strategic goals through education, research, and support for the delivery of the highest quality of care by the Society’s nearly 45,000 members.

Read Dr. Hudis’ Q&A on ASCO Connection.

View current ASCO disclosure here.

Everett E. Vokes, MD, FASCO
ASCO President
x

Dr. Vokes specializes in head and neck and lung cancers. He is the John E. Ultmann Professor, chair of the Department of Medicine, and physician-in-chief at the University of Chicago Medicine and Biological Sciences. He is the former leader of the Respiratory Committee of the Alliance ( formerly  Cancer and Leukemia Group B ) and serves on the editorial boards of several journals. He is a past chair of the Annual Meeting Education Committee, Annual Meeting Scientific Program Committee, and a member of the Conquer Cancer Development and Fundraising Committee, and the Cancer.Net Editorial Board. He served as an elected member of the ASCO Nominating Committee, and on the Board of Directors from 2009-2012.

View current ASCO disclosure here

Eric P. Winer, MD, FASCO
ASCO President-Elect
x

Dr. Winer has been elected to serve as the ASCO President in 2022-2023. He is the chief clinical development officer, senior vice president for medical affairs, chief of the Division of Breast Oncology, and the Thompson Chair in Breast Cancer Research at Dana-Farber Cancer Institute. He is also a professor of medicine at Harvard Medical School. Dr. Winer served on the ASCO Board of Directors from 2011 to 2015, and has served as chair of the ASCO Government Relations Committee, Cancer Communications Committee, and Health Services Research Committee, among numerous volunteer roles. He is the 2017 recipient of ASCO’s Gianni Bonadonna Breast Cancer Award and Lecture.

View current ASCO disclosure here.

Lori J. Pierce, MD, FASTRO, FASCO
Chair of the Board
x

Dr. Pierce is a radiation oncologist, professor, and Vice Provost for Academic and Faculty Affairs at the University of Michigan. She is also director of the Michigan Radiation Oncology Quality Consortium. A national leader in breast cancer research, Dr. Pierce was previously a Senior Investigator at the National Cancer Institute, National Institutes of Health and in 1992, joined the faculty at the University of Michigan where she has focused her career primarily on the treatment of breast cancer.

An active ASCO member since 1992, Dr. Pierce is a past member of multiple ASCO committees including the Government Relations Committee, Annual Meeting Scientific Program Committee, and the Conquer Cancer Foundation Nominating Committee, and she served as a mentor for the Leadership Development Program from 2015 to 2018. She previously served on the ASCO Board of Directors from 2010 – 2014 and was named a Fellow of ASCO (FASCO) in 2015. 

With over 180 manuscripts and book chapters published, Dr. Pierce has received numerous teaching and leadership awards including the American Association of Women Radiologists' Marie Curie Award and the Hologic, Inc Endowed Women Who Conquer Cancer Mentorship Award. In 2018, she was elected into the National Academy of Medicine. Most recently, Dr. Pierce was selected as the 2019 Woman of the Year by the United Way of Washtenaw County (UWWC) of Michigan.

Dr. Pierce completed her undergraduate degree in biomedical engineering at the University of Pennsylvania and her medical degree at Duke University. She completed her internship at the Thomas Jefferson University Hospital and her residency and chief residency in Radiation Oncology at the University of Pennsylvania.

View current ASCO disclosure here.

Howard A. Burris III, MD, FACP, FASCO
Past President; Chair, Board of Conquer Cancer, the ASCO Foundation
x

Dr. Burris serves as president and chief medical officer of Sarah Cannon, as well as the executive director, drug development for the research institute. He is an associate of Tennessee Oncology, PLLC, where he practices medical oncology.

Dr. Burris' clinical research career has focused on the development of new cancer agents with an emphasis on first in human therapies, having led the trials of many novel antibodies, small molecules, and chemotherapies now FDA approved, including ado-trastuzumab emtansine, everolimus, and gemcitabine. In 1997, he established in Nashville the first community based early phase drug development program, which grew into the Sarah Cannon Research Institute. He has authored over 400 publications and 700 abstracts. Sarah Cannon has now dosed over 350 first in human anticancer therapies and enrolls more than 3000 patients per year into clinical trials.

Dr. Burris served as the elected president of ASCO in 2019-2020. He currently serves as the Chair of the Society's Board and also as the Chair of the Board of ASCO’s Conquer Cancer Foundation. Additionally in 2014, Dr. Burris was selected by his peers as a Giant of Cancer Care for his achievements in drug development.

Dr. Burris completed his undergraduate education at the United States Military Academy at West Point, his medical degree at the University of South Alabama, and his internal medicine residency and oncology fellowship at Brooke Army Medical Center in San Antonio. While in Texas, he also served as the Director of Clinical Research at The Institute for Drug Development of the Cancer Therapy and Research Center and The University of Texas Health Science Center. He attained the rank of lieutenant colonel in the US Army, and among his decorations, he was awarded a Meritorious Service Medal with oak leaf cluster for his service in Operation Joint Endeavor.  

View current ASCO disclosure here.

Laurie E. Gaspar, MD, MBA, FASTRO, FACR, FASCO
Treasurer
x

Dr. Gaspar grew up in Toronto, Ontario and completed medical school and a residency in radiation oncology at Western University.  Later, after moving to the United States she completed her Masters of Business Administration (MBA) at the University of Michigan.

Dr. Gaspar has been active in many national and international committees, including the ASCO Publications Committee and ASCO’s Annual Program Committees. She is also involved with the American Board of Radiology (ABR), the American Society for Radiation Oncology (ASTRO), NRG (formally RTOG), the International Society for the Study of Lung Cancer (IASLC), and SWOG. She is a Co-Chair of the NCI Thoracic Malignancy Steering Committee. Dr. Gaspar is on the editorial board of Clinical Lung Cancer and Advances in Radiation Oncology. She is the author of more than 200 published articles.

Dr. Gaspar was Professor and Chair of the Department of Radiation Oncology at the University of Colorado for more than 15 years. She is currently Professor Emerita in the Department of Radiation Oncology at the University of Colorado, as well as a staff radiation oncologist at Banner MDA in Northern Colorado.  Dr. Gaspar maintains a long-standing interest in the management of brain tumors and lung cancer.

Read Dr. Gaspar’s Q&A on ASCO Connection.

View current ASCO disclosure here.

Elizabeth A. Mittendorf, MD, PhD, MHCM, FASCO
Board Seat: Surgical Oncologist; Treasurer-Elect
x

Dr. Mittendorf is the Rob and Karen Hale Distinguished Chair in Surgical Oncology at Brigham and Women’s Hospital, Associate Chair of Research for the Department of Surgery, and co-leader of the Breast Program at Dana-Farber / Harvard Cancer Center. She has previously served on ASCO’s Annual Meeting Scientific Program Committee and as chair of the Conquer Cancer Grants Selection Committee and chair of the ASCO-SITC Clinical Immuno-Oncology Symposium Scientific Program Committee. Dr. Mittendorf is currently the Treasurer-Elect and will serve as the Treasurer of the Society Board of Directors beginning June 2022.

View current ASCO disclosure here.

Ethan M. Basch, MD, MSc, FASCO
Board Seat: Undesignated Specialty
x

Dr. Basch is chief of the division of oncology at the University of North Carolina and physician-in-chief of the North Carolina Cancer Hospital. He is the Richard M Goldberg Distinguished Professor in Medical Oncology and professor of health policy & management. He serves as director of the cancer outcomes research program at UNC Lineberger Comprehensive Cancer Center, as associate editor at Journal of the American Medical Association, and on the editorial board of the Journal of Oncology Practice. He has previously served on the NCI Board of Scientific Advisors, on the Methodology Committee of PCORI, as chair of the ASCO Clinical Practice Guidelines Committee, the CancerLinQ Advisory Group, the Annual Meeting Education Committee, and the Quality of Care Council.

Read Dr. Basch’s Q&A on ASCO Connection.

View current ASCO disclosure here.

A. William Blackstock, MD, FASCO
Board Seat: Radiation Oncologist
x

Dr. Blackstock is Professor and Chair of the Department of Radiation Oncology at the Wake Forest University (WFU) School of Medicine and Director of the Clinical Research Program at the Comprehensive Cancer Center at Wake Forest Baptist Medical Center. He received his undergraduate degree from WFU and his medical degree from the East Caroline University Brody School of Medicine. He completed a residency in radiation oncology at the University of North Carolina at Chapel Hill and a three-year NCI-funded fellowship in translational Radiation Oncology. He has been Chair at WFU for the past 8 years.

Dr. Blackstock remains active in translational clinical research, having served as vice-chair of the GI Committee in the Alliance/CALGB cooperative group and co-vice chair of the Radiation Oncology committee. In addition to serving on the NCI Clinical Oncology study section (2003-2006), he served on the NCI Pancreatic Task Force, Gastrointestinal Steering committee and co-chair of the Thoracic Malignancy Steering Committee (2013-2016). He recently completed service on the NCI Board of Scientific Counsel Intramural Program.

Dr. Blackstock has been an active ASCO member for almost 20 years, serving on the grants selection and communications committees. He has chaired the Gastrointestinal Cancer Program subcommittee and the ASCO membership committee (2008-2009). Other activities include participating in the ASCO Leadership Development Working Group and Health Disparities Advisory Group.

Dr. Blackstock has been the lead investigator of several NCI-funded grants including principal investigator of an NCI-funded T32 fellowship focused on Translational Radiation Oncology. He currently serves on the external advisory board for several NCI/NIH funded training programs. He has published over 100 peer-reviewed manuscripts and book chapters and continues to serve on the editorial board for several journals including the Journal of Clinical Oncology (2007-2009).

View current ASCO disclosure here.

Lisa A. Carey, MD, FASCO
Board Seat: Undesignated Specialty
x

Dr. Carey is Chief of Hematology/Oncology, Associate Director of Clinical Sciences, and the Richardson and Marilyn Jacobs Preyer Distinguished Professor in Breast Cancer Research at the University of North Carolina Lineberger Comprehensive Cancer Center. She is also Physician-In-Chief of the N.C. Cancer Hospital. Dr. Carey is a member of ASCO’s Breast Cancer Guideline Advisory Group. She previously served the Society as chair of the Nominating Committee, chair of the Professional Development Committee, track leader of the Annual Meeting Education Committee, and a member of the Journal of Clinical Oncology editorial board.

View current ASCO disclosure here

Lee M. Ellis, FACS, MD, FASCO
Board Seat: Undesignated Specialty
x

Dr. Ellis is the Ruben Distinguished Chair in Gastroenterology Cancer Research and a professor in the Departments of Surgical Oncology, and Molecular & Cellular Oncology at The University of Texas MD Anderson Cancer Center (MDACC), Executive Director for Translational Research, Global Academic Programs (MDACC), as well as the Vice Chair of Translational Medicine at SWOG. Previously, he served as Interim Chair, Department of Cancer Biology from 2008 to 2012, Director of the Metastasis Research Center from 2010 to 2012, and Director of the Colorectal Cancer Translational Research Program from 2007 to 2013, all at MDACC.

Since joining ASCO in 1994, Dr. Ellis has served on numerous committees with recent committee service on the Nominating Committee (2013-2016; chair, 2015-2016), the Best Practices in Clinical Cancer Trials Workshop (2015-2016), the Cancer Research Committee (2011-2014; chair 2012-3013), and the Cancer Education Committee (2011-2013; Tumor Biology track leader, 2012-2013). He served as a faculty member of the ASCO/AACR Methods in Clinical Cancer Research Workshop in 2007-2013 and was co-director in 2010-2013. He was named a Fellow of ASCO (FASCO) in 2014, and he currently serves as the ASCO Board Liaison to the Society’s Research Committee. He is also a member of the Association for Clinical Oncology Board of Directors and the Association Board’s Executive Committee.

In addition to his ASCO involvement, Dr. Ellis serves as the co-chair of the National Cancer Institute's (NCI) National Clinical Trials Network Core Correlative Sciences Committee (NCTN-CCSC), Vice Chair emeritus of the NCI Colon Cancer Task Force, and recently completed his term as Vice Chair of the Hope Foundation, SWOG’s philanthropic arm. He also serves on the board of directors of the Canines-N-Kids Foundation. Dr. Ellis has a special interest in preclinical data reproducibility and has published several important manuscripts in this area. He has also met with NCI, NIH, and National Academies of Science (NAS) leaders regarding the importance of this issue and how to address this problem. Dr. Ellis has also served on a NAS committee that focused on issuing recommendations to decrease the regulatory burden of research (2014-2016), and as faculty and then co-director (2015-present) of the AACR-EORTC-ESMO workshop on Methods in Clinical Cancer Research in Europe. In 2017, Dr. Ellis received the Flance-Karl Award from the American Surgical Association for his “seminal contributions in understanding colorectal cancer biology.” He currently serves on several data safety monitoring committees, including the ECOG/ACRIN DMC, and he is a member the Scientific Audit Committee of the EORTC (Brussels, Belgium), and a member of the organizing committee for ESMO’s Targeted Anti-Cancer Therapy  (TAT) Annual Meeting.

Dr. Ellis received his medical degree from the University of Virginia; he performed his residency at the University of Florida, and his fellowship at MDACC.  

Read Dr. Ellis’ Q&A on ASCO Connection.

View current ASCO disclosure here.

Tara O. Henderson, MD, MPH, FASCO
Board Seat: Pediatric Oncologist
x

Dr. Henderson is a professor of pediatrics, Division Chief of Pediatric Hematology, Oncology and Stem Cell Transplantation and director of the Childhood Cancer Survivor Center at the University of Chicago, and co-leader of the cancer prevention and control program for the University of Chicago Comprehensive Cancer Center. She is a graduate of the 2018 President Leadership Scholars program and a 2015 graduate of the ASCO Leadership Development Program. Dr. Henderson is the chair of the ASCO Adolescent and Young Adult (AYA) Survivorship Work Group and a past member of several ASCO committees, including the Government Relations Committee, the Survivorship Guideline Advisory Group, the Conquer Cancer Grants Selection Committee and Osteoporosis in Survivors of Adult Cancers Expert Panel. She is the past chair of the Cancer Survivorship Committee, a member of the Society Board’s Audit Committee and a liaison to the Conquer Cancer Grants Selection Committee.

View current ASCO disclosure here.

 

Mariana Chavez Mac Gregor, MD, MSc
Board Seat: Undesignated Specialty
x

Dr. Chavez Mac Gregor is an Associate Professor in the Department of Health Services Research and an Associate Professor in the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center. She is Co-Chair of the ASCO Breast Cancer Guideline Advisory Group and a member of the Resource-Stratified Guideline Advisory Group. She has served as Chair of the Clinical Practice Committee and the Methodology Subcommittee, along with many other volunteer roles, including serving as a grant reviewer and as a member of the Women’s Networking Center Task Force. She is a 2018–2019 participant in ASCO’s Leadership Development Program, and is the recipient of several Merit Awards and the Breast Cancer Advanced Clinical Research Award from Conquer Cancer, the ASCO Foundation.

View current ASCO disclosure here.

Tony S. K. Mok, MD, FRCPC, FASCO
Board Seat: International Oncologist
x

Dr. Mok was trained at the University of Alberta, Canada and he subsequently completed a fellowship in medical oncology at the Princess Margaret Hospital in Canada. After working as a community oncologist in Toronto, Canada for seven years, he returned to Hong Kong in 1996 to pursue an academic career.

He is Li Shu Fan Medical Foundation Named Professor of Clinical Oncology and Chair of Clinical Oncology at The Chinese University of Hong Kong (Hong Kong). His main research interest focuses on biomarker and molecular targeted therapy in lung cancer. He co-founded the Lung Cancer Research Group, and has led a number of important multinational clinical trials, which include the IPASS (IRESSA Pan-Asia Study), a landmark study that established the role of first-line gefitinib in patients with EGFR mutation.

Prof. Mok has contributed to over 220 articles in international peer-reviewed journals, including the New England Journal of Medicine, Science, Lancet and Journal of Clinical Oncology, and contributed to multiple editorials and textbooks. He is active and experienced in serving the academic societies. He is now Fellow of American Society of Clinical Oncology (FASCO), Past Chair of the ASCO International Affairs Committee, Treasurer and Past President of the International Association for the Study of Lung Cancer (IASLC), a member of the ASCO Publications Committee and Vice Secretary of the Chinese Society of Clinical Oncology (CSCO).

He is closely affiliated with the oncology community in China, and has received an Honorary Professorship at Guang Dong Province People’s Hospital, Guest Professorship at Peking University School of Oncology, Visiting Professorship at Shanghai Jiao Tong University and West China School of Medicine/West China Hospital, Sichuan University. He is an Associate Editor on Thoracic Oncology for Journal of Clinical Oncology.  He has also authored eight books in Chinese and hosted three television series in Hong Kong.

Read Dr. Mok’s Q&A on ASCO Connection.

View current ASCO disclosure here.

Taofeek K. Owonikoko, MD, PhD, MS
Board Seat: Medical Oncologist
x

Dr. Owonikoko is the Chief of the Division of Hematology and Oncology, co-Leader of the Cancer Therapeutics Program, and Associate Director for Translational Research at the University of Pittsburgh Medical Center Hillman Cancer Center. He is a Professor in the Department of Medicine and the Stanley M. Marks – OHA Endowed Chair in Hematology/Oncology Leadership at the University of Pittsburgh. He previously served as the Director of Thoracic Oncology, Co-Leader of the Discovery and Developmental Therapeutics Research Program, and Chair of the Aerodigestive Malignancies Working Group at Winship Cancer Institute. Dr. Owonikoko has chaired the ASCO Annual Meeting Education Committee; has served as track leader and member of the Annual Meeting Scientific Program and Education Committees; and as a mentor in ASCO’s Diversity Mentoring Program. He is a 2015–2016 participant in ASCO’s Leadership Development Program.

View current ASCO disclosure here.

Elizabeth R. Plimack, MD, MS
Board Seat: Undesignated Specialty
x

Dr. Plimack serves as chief of the division of genitourinary medical oncology at Fox Chase Cancer Center in Philadelphia. She is a professor of medical oncology and the director of genitourinary clinical research at the center. She is a past member and track chair of the ASCO Scientific Program Committee, Genitourinary (Non-Prostate) Cancer track. She serves as a member on the Board’s Finance Committee and is the Board Liaison to the Cancer Communications Committee. Dr. Plimack received a Conquer Cancer Merit Award at the 2008 Genitourinary Cancers Symposium.

Read Dr. Plimack's Q&A on ASCO Connection.

View current ASCO disclosure here.

Gladys I Rodriguez, MD
Board Seat: Community Oncologist
x

Dr. Rodriguez is a medical oncologist and hematologist, Vice President of Clinical Research at South Texas Oncology and Hematology, PA at the START Center for Cancer Care, and Co-Manager of South Texas Accelerated Research Therapeutics (START). She has served as a member of the ASCO Government Relations Committee, State Affiliate Council, and COVID-19 Road to Recovery Task Force, among other volunteer roles. She was honored as an ASCO Advocacy Champion in 2019 and 2020. Dr. Rodriguez is Past President and Board member of the Texas Society of Clinical Oncology (TxSCO), an ASCO State Affiliate.

View current ASCO disclosure here.

Enrique Soto Perez De Celis, MD, MSc
Board Seat: International Oncologist
x

Dr. Soto Pérez is a geriatric oncologist and researcher in the Department of Geriatrics at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City. On the Board, he serves as a liaison to the ASCO Education Council, and is a member of the Society’s Finance Committee. He also currently serves on several ASCO committees, including the Journal of Global Oncology Editorial Board, Social Media Working Group, Diversity and Inclusivity Task Force, Technology Research Group, and Publishing Research Group. He has previously served on the AM Education Committee and the Grants Selection Committee. He received a 2019 Conquer Cancer Career Development Award. Previously, Dr. Soto has served on several other ASCO research groups and advisory panels, contributed to the ASCO Connection and ASCO Daily News, and was selected for a Journal of Global Oncology Editorial Fellowship.

Read Dr. Soto’s Q&A on ASCO Connection.

View current ASCO disclosure here.

 

Michael A. Thompson, MD, FASCO, PhD
Board Seat: Community Oncologist
x

Dr. Thompson is a medical oncologist and hematologist. He is the medical director for the Early Phase Cancer Research Program as well as the co-director of Oncology Precision Medicine Program at Advocate Aurora Health. He is a graduate of ASCO’s Leadership Development Program, has served as chair of the ASCO Annual Meeting Education Committee and the Research Community Forum Council, and is a current member of several ASCO volunteer groups. 

Read Dr. Thompson’s Q&A on ASCO Connection.

View current ASCO disclosure here.

Tracey Weisberg, MD, FASCO
Board Seat: Community Oncologist
x

Dr. Weisberg is the past president and lead physician of New England Cancer Specialists for the past 10 years, manages an active breast cancer practice, has been a principal investigator on 40 clinical trials, and oversees medical house staff at the Maine Medical Center Oncology inpatient unit. An active member of ASCO since 1990, Dr. Weisberg is a past chair of the State Affiliate Council and has been involved in a number of ASCO initiatives, including the ASCO Rural Task Force, the CancerLinQ Advisory Committee, the Strategic Planning Task Force, and the Payment Reform Implementation Workgroup, to name a few.

Outside of ASCO, Dr. Weisberg has have served as a board member with Hospice of Southern Maine as well as Northern New England Oncology Association.

Read Dr. Weisberg’s Q&A on ASCO Connection.

View current ASCO disclosure here.